BlackRock Amends Organon Stake, Maintains Passive Position
Ticker: OGN · Form: SC 13G/A · Filed: Jan 23, 2024 · CIK: 1821825
| Field | Detail |
|---|---|
| Company | Organon & CO. (OGN) |
| Form Type | SC 13G/A |
| Filed Date | Jan 23, 2024 |
| Risk Level | low |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, passive-investment, amendment, pharmaceuticals
TL;DR
**BlackRock still owns a big chunk of Organon, but it's just a passive investment.**
AI Summary
BlackRock Inc. filed an amended SC 13G/A on January 23, 2024, disclosing its ownership in Organon & Co. as of December 31, 2023. This filing, Amendment No. 3, indicates BlackRock's continued significant passive stake in the pharmaceutical company. For investors, this means a major institutional investor maintains confidence in Organon, which can be a positive signal, but it doesn't suggest any active management changes or activist intentions.
Why It Matters
This filing confirms BlackRock, a massive institutional investor, still holds a significant, but passive, stake in Organon & Co., which can influence investor perception and stock stability.
Risk Assessment
Risk Level: low — This filing is routine and indicates a passive investment, posing minimal new risk to investors.
Analyst Insight
Investors should note BlackRock's continued passive stake in Organon & Co. as a sign of institutional confidence, but this filing alone doesn't suggest any immediate catalysts or changes in company direction.
Key Players & Entities
- BlackRock Inc. (company) — the reporting person and institutional investor
- Organon & Co. (company) — the subject company whose securities are being reported
- December 31, 2023 (date) — the date of the event requiring the filing
- January 23, 2024 (date) — the filing date of the SC 13G/A
- 68622V106 (other) — the CUSIP number for Organon & Co. Common Stock
FAQ
What type of filing is this and what does it indicate?
This is an SC 13G/A filing, which is an amendment (Amendment No. 3) to a Schedule 13G. It indicates that BlackRock Inc. is reporting its beneficial ownership of Organon & Co. common stock as a passive investor, meaning they do not intend to influence or control the company.
Who is the reporting person in this filing?
The reporting person is BlackRock Inc., a major asset management firm based at 50 Hudson Yards, New York, NY.
What company's stock is being reported on?
The filing reports on the Common Stock of Organon & Co., a pharmaceutical preparations company located at 30 Hudson Street, Jersey City, NJ.
What was the 'Date of Event Which Requires Filing of this Statement'?
The 'Date of Event Which Requires Filing of this Statement' was December 31, 2023, indicating the ownership position as of the end of the last calendar year.
Under which rule was this Schedule 13G filed?
This Schedule 13G was filed under Rule 13d-1(b), which is typically used by institutional investors (like BlackRock) who acquire more than 5% of a company's stock in the ordinary course of business and without the intent to influence or control the issuer.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on January 23, 2024 regarding Organon & Co. (OGN).